Pakistan’s healthcare landscape has entered a pivotal phase in the management of diabetes and obesity. For years, advanced ...

Pakistan's healthcare sector has entered a transformative phase in the management of diabetes and obesity, as locally ...

A recent Northwestern Medicine study has identified novel neural circuits modulated by the diabetes and obesity-management ...

MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular ...

Fractyl Health Inc. (NASDAQ:GUTS) is one of the best young stocks with huge upside potential. On October 7, Fractyl Health ...

The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

Chugai Pharma concludes license agreement with Roche for CT-388, a long-acting GLP-1/GIP receptor agonist: Tokyo Saturday, October 11, 2025, 11:00 Hrs [IST] Chugai Pharmaceutical ...

BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes medications — also known as GLP-1 and GIP injections — are changing the way we ...

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster ...